Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00869
|
|||||
| Drug Name |
Terazosin
|
|||||
| Synonyms |
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((tetrahydro-2-furanyl)carbonyl)piperazine; 1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine; 6,7-bis(methyloxy)-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; 6,7-dimethoxy-2-[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]quinazolin-4-amine; A 45975; A-45975; Abbott 45975; Blavin; Flumarc; Fosfomic; Hytracin; Hytrin; Hytrin (TN); Terazosabb; Terazosabb (TN); Terazosin (INN); Terazosin [INN:BAN]; Terazosina; Terazosina [INN-Spanish]; Terazosine; Terazosine [INN-French]; Terazosinum; Terazosinum [INN-Latin]; Trazosin HCl; Vasomet; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl](tetrahydrofuran-2-yl)methanone; [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Therapeutic Class |
Anticancer Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C19H25N5O4
|
|||||
| Canonical SMILES |
COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC
|
|||||
| InChI |
InChI=1S/C19H25N5O4/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22)
|
|||||
| InChIKey |
VCKUSRYTPJJLNI-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 63590-64-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 387.4 | Topological Polar Surface Area | 103 | ||
| Heavy Atom Count | 28 | Rotatable Bond Count | 4 | |||
| Hydrogen Bond Donor Count | 1 | Hydrogen Bond Acceptor Count | 8 | |||
| XLogP |
1.4
|
|||||
| PubChem CID | ||||||
| ChEBI ID |
ChEBI:9445
|
|||||
| TTD Drug ID | ||||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.